Program
Anti-CD20 Monoclonal Antibody MIL62
Also written as “MIL62”, “Recombinant Humanized Monoclonal Antibody MIL62 Injection” and “Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide”.
Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, Membranous · Lymphoma, Follicular · Neuromyelitis Optica · Lupus Nephritis, led by 2 companies.
Drug pageAnti-CD20 Monoclonal Antibody MIL62: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Mabworks Biotechits history only | 96 open or running | phase 3since Apr 5, 2021 | Sep 18, 2019 | Dec 2028phase 3 · NCT07405970 |
| InnoCare Pharmaits history only | 11 open or running | phase 2since Mar 5, 2020 | Mar 5, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 18, 2019First study: phase 1 study in CD20-positive B Cell Non-Hodgkin LymphomaNew to Beijing Mabworks BiotechBeijing Mabworks Biotech · NCT04103905 · 27 enrolled · China
- Sep 27, 2019Phase 2 study in Lymphoma, FollicularBeijing Mabworks Biotech · NCT04110301 · 53 planned · China
- Mar 5, 2020InnoCare Pharma’s first study: phase 2 study in B-cell Lymphoma RecurrentNew to InnoCare PharmaInnoCare Pharma · NCT04304040 · 43 enrolled · China
- Apr 5, 2021Phase 3 study in Lymphoma, FollicularBeijing Mabworks Biotech · NCT04834024 · 168 planned · China
- Mar 29, 2022Phase 3 study in Neuromyelitis OpticaBeijing Mabworks Biotech · NCT05314010 · 102 enrolled · China
- May 26, 2022Phase 2 study in Primary Membranous NephropathyBeijing Mabworks Biotech · NCT05398653 · 94 enrolled · China
- Mar 8, 2023Phase 2 study in Lupus Erythematosus, SystemicBeijing Mabworks Biotech · NCT05796206 · 123 enrolled · China
- May 8, 2023Phase 3 study in Primary Membranous NephropathyBeijing Mabworks Biotech · NCT05862233 · 150 enrolled · China
- Jun 23, 2025Phase 2 study in Lupus NephritisBeijing Mabworks Biotech · NCT07044115 · 41 enrolled · China
- Feb 5, 2026Phase 3 study in Lupus Erythematosus, SystemicBeijing Mabworks Biotech · NCT07405970 · 316 planned · China
Ahead
- Dec 2028Primary completion: phase 3 study in Lupus Erythematosus, SystemicBeijing Mabworks Biotech · NCT07405970
TargetBeta
“A glyco-engineered recombinant humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, ”NCIt, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07405970Lupus Erythematosus, Systemic · China | 3 | Recruiting | Beijing Mabworks Biotech | Dec 2028 | 316 |
| NCT07044115Lupus Nephritis · China | 2 | Active, not recruiting | Beijing Mabworks Biotech | Jan 16, 2025 | 41 |
| NCT05862233Primary Membranous Nephropathy · China | 3 | Active, not recruiting | Beijing Mabworks Biotech | May 13, 2025 | 150 |
| NCT05796206Lupus Erythematosus, Systemic · China | 2 | Completed | Beijing Mabworks Biotech | Nov 21, 2024 | 123 |
| NCT05398653Primary Membranous Nephropathy · China | 2 | Completed | Beijing Mabworks Biotech | Mar 4, 2025 | 94 |
| NCT05314010Neuromyelitis Optica · China | 3 | Active, not recruiting | Beijing Mabworks Biotech | Feb 21, 2025 | 102 |
| NCT04834024Lymphoma, Follicular · China | 3 | Recruiting | Beijing Mabworks Biotech | Mar 2025 | 168 |
| NCT04304040B-cell Lymphoma Recurrent · China | 2 | Active, not recruiting | InnoCare Pharma | Dec 30, 2025 | 43 |
| NCT04110301Lymphoma, Follicular · China | 2 | Recruiting | Beijing Mabworks Biotech | Jan 9, 2024 | 53 |
| NCT04103905CD20-positive B Cell Non-Hodgkin Lymphoma · China | 1 | Completed | Beijing Mabworks Biotech | May 30, 2019 | 27 |
How it is read
Names in the registry
- “MIL62”, 6 entries
- “Recombinant Humanized Monoclonal Antibody MIL62 Injection”, 3 entries
- “Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide”, 1 entry
- “Recombinant humanized monoclonal antibody MIL62 injection”, 1 entry
Codes read as this program: MIL62.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 2 studies
- Glomerulonephritis, Membranous, 2 studies
- Lymphoma, Follicular, 2 studies
- Neuromyelitis Optica, 1 study
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.